A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset
of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving
SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2
actuations twice daily.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate